Rubicon Research Ltd.

Caution: For private circulation only.Please note that Money Times is for circulation among paid subscribers only. Any attempt to share your access to our website or forwarding your copy to a non-subscriber will disqualify your membership and we will be compelled to stop your supply and forfeit your subscription thereafter without any refund to you.

By Nitin Negandhi

Rubicon Research Ltd.

Founded in 1999, Rubicon Research Ltd. (RRL) was established by Pratibha Pilgaonkar, who brings extensive experience from leading pharma companies such as GSK Pharma, Ciba Geigy, and Sun Pharma. The company is coming out with an IPO comprising a fresh issue of shares worth Rs.500 crore and an offer for sale aggregating up to Rs.878 crore by General Atlantic Singapore.

Proceeds from the fresh issue will be utilized for future growth initiatives, debt repayment, and general corporate purposes. Promoter holding will reduce from 78% to 62.1% post-issue.

Business:

RRL operates in the pharmaceutical research and innovation segment, focusing on R&D-driven product development and high-quality formulations. It has a strong presence in the US generics and specialty markets, with five key customers in the USA contributing over 70% of its revenue. The company has seventy-two active Abbreviated New Drug Applications (ANDAs), nine active New Drug Applications (NDAs) and one Over-the-Counter (OTC) monograph listed with the USFDA. Additionally, seventeen products await USFDA approval, and sixty-three more are under various stages of development.

In FY22, RRL strengthened its distribution network by launching its own distribution arm, AdvaGen Pharma, which holds licenses to sell products across forty-nine US states. It also acquired Validus, a branded formulations company with presence in forty-four US states. The company currently operates four manufacturing facilities and two R&D centres, all approved by the USFDA.

RRL’s topline grew at a robust CAGR of 75.9% between FY23–FY25, turning from a loss of Rs.17 crore to a net profit of Rs.134 crore during the same period. For Q1FY26, revenue rose 11% YoY to Rs.352 crore with net profit of Rs.43 crore.

Financial Performance:                                                (Rs. in crore)

Peer Comparison for FY25:                                               (Rs. in crore)

Risk factors:

Major risks for this IPO and for Rubicon are:

– The hanging US tariff sword

– Heavy dependence on a few customers

– High working capital requirements

At the upper band of the IPO, the P/E ratio is expensive at 56 times compared to large pharma companies like Sun, Lupin, and Aurobindo. Its revenue-to-market-cap ratio (post-listing) of seven times is comparable to that of Sun Pharma. However, Sun Pharma is an established player with a highly diversified product portfolio, unlike Rubicon.

The issue, which opened on 9th October, is oversubscribed by 2.5 times and is expected to be heavily oversubscribed if the GMP is any indication. Listing gains are likely, but caution is advised, and investors should wait for the company’s future performance to justify the higher P/E ratio.

Disclaimer:

The writer is not a SEBI-registered analyst. He and his associates may or may not participate in the IPO. This write-up is for educational purposes only, and investors should consult their financial advisors before investing. The grey market premium (GMP) is merely an indicator and should not be relied upon for investment decisions.